NCT06556004View on ClinicalTrials.gov

Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 2, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

March 31, 2025

Conditions
Melanoma Stage IIIcMelanoma Stage IV
Interventions
BIOLOGICAL

TRIMELVAX

The safety of this immunotherapeutic compound will be tested in patients with advanced melanoma and will secondarily evaluate the induced immune response.

Trial Locations (2)

7510916

Hospital Salvador, Santiago

8380000

Faculty of Medicine, University of Chile, Santiago

All Listed Sponsors
collaborator

Hospital del Salvador

OTHER

lead

University of Chile

OTHER